Last quarter (Q ), Bone Biologics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Bone Biologics's net income was $-1.55M. See Bone Biologics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	$ 0.00	$ 0.00
Gross Profit	-	-	-	-	$ 0.00	$ 0.00
Operating Expense	$ 3.13M	$ 9.43M	$ 3.67M	$ 1.10M	$ 825.01K	$ 2.45M
Operating Income	$ -3.13M	$ -9.43M	$ -3.67M	$ -1.10M	$ -825.01K	$ -2.45M
Net Non Operating Interest Income Expense	$ 1.87K	$ 1.87K	$ -731.71K	$ -507.61K	$ -998.08K	$ -975.77K
Other Income Expense	$ -477.70K	$ -477.70K	$ -2.91M	-	-	-
Pretax Income	$ -2.65M	$ -8.95M	$ -1.48M	$ -1.61M	$ -1.82M	$ -3.42M
Tax Provision	-	-	-	$ 1.60K	$ 1.60K	$ 1.60K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -2.65M	$ -8.90M	$ -1.48M	$ -1.61M	$ -1.82M	$ -3.42M
Basic EPS	$ -5.80	$ -34.01	$ -0.13	$ -0.35	$ -0.63	$ -1.18
Diluted EPS	$ -5.80	$ -34.01	$ -0.13	$ -0.35	$ -0.63	$ -1.18
Basic Average Shares	$ 20.76M	$ 263.14K	$ 11.42M	$ 4.60M	$ 2.91M	$ 2.92M
Diluted Average Shares	$ 20.76M	$ 263.14K	$ 11.42M	$ 4.60M	$ 2.91M	$ 2.92M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 3.13M	$ 9.43M	$ 3.67M	$ 1.10M	$ 825.01K	$ 2.45M
Net Income From Continuing And Discontinued Operation	$ -8.90M	$ -8.90M	$ -1.48M	$ -1.61M	$ -1.82M	$ -3.42M
Normalized Income	$ -4.14M	$ -7.07M	-	-	$ -1.82M	$ -3.42M
Interest Expense	-	-	-	-	$ 998.08K	$ 975.77K
EBIT	$ -2.66M	$ -8.95M	$ -1.48M	$ -805.58K	$ -825.01K	$ -2.45M
EBITDA	$ -2.66M	$ -8.95M	$ -1.48M	$ -805.58K	$ -825.01K	$ -2.45M

Currency in USD

Bone Biologics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing